The cancer anorexia-cachexia syndrome: Myth or reality?

Supportive Care in Cancer

Volumn 18, Issue 2, 2010, Pages 265-272

  Lasheen, Wael ^a   Walsh, Declan ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Anorexia; Anorexia cachexia; Cachexia; Cancer; Palliative care; Prognosis; Survival; Symptom burden; Symptoms

Indexed keywords

ADULT; AGED; ANOREXIA; ARTICLE; BODY WEIGHT; CACHEXIA; CANCER ANOREXIA CACHEXIA SYNDROME; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; CONSTIPATION; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSPHAGIA; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; SATIETY; SURVIVAL TIME; SYNDROME; TASTE DISORDER; VOMITING; WEAKNESS; WEIGHT REDUCTION; COMORBIDITY; COST OF ILLNESS; EPIDEMIOLOGY; HEALTH SURVEY; MIDDLE AGED; NEOPLASM; PALLIATIVE THERAPY; PREVALENCE; SEX RATIO; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANOREXIA; CACHEXIA; CAUSALITY; COMORBIDITY; COST OF ILLNESS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; POPULATION SURVEILLANCE; PREVALENCE; PROGNOSIS; QUESTIONNAIRES; SEX DISTRIBUTION; SURVIVAL RATE; SYNDROME; WEIGHT LOSS;

EID: 76549088027     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-009-0772-6     Document Type: Article

References (23)

1. http://www.biblegateway.com Accessed 07/2009.
2. Loprinzi CL, Sloan JA, Rowland KM (2003) Methodologic issues regarding cancer anorexia/cachexia trials. In: Portenoy RK, Bruera E (eds) Issues in palliative care research. Oxford University Press, Inc, New York, pp 25-40.
3. Bennani-Baiti N, Walsh D (2009) What is the cancer anorexiacachexia syndrome? J R Coll Physicians Edinb 39:257-262.
4. Grosvenor M, Bulcavage L, Chlebowski RT (1989) Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. Cancer 63(2):330-334.
5. Strasser F, Bruera E (2002) Cancer anorexia cachexia syndrome: epidemiology, pathogenesis and assessment. In: Ripamonti C, Bruera E (eds) Gastrointestinal symptoms in advanced cancer. Oxford University, New York, pp 39-80.
6. Fearon KC, Voss AC, Hustead DS, Cancer Cachexia Study Group (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345-1350.
7. Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG (2005) Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative caredcorrelations with food intake, metabolism, exercise capacity, and hormones. Cancer 103(10):2189-2198.
8. Perboni S, Mantvovani G, Inui A, Takimoto Y (2005) Anorexia: central and peripheral mechanisms. In: Hofbauer KG, Anker S, Inui A, Nicholson JR (eds) Pharmacotherapy of Cachexia. CRC Press, Boca Raton, pp 17-30.
9. Walsh D, Donnelly S, Rybicki L (2000) The symptoms of advanced cancer: relationship to age, gender, and performance status in 1, 000 patients. Support Care Cancer 8(3):175-179.
10. Blackburn GL, Bistrian BR, Maini BS, Schlamm HT, Smith MF (1977) Nutritional and metabolic assessment of the hospitalized patient. J Parenter Enteral Nutr 1:11-22.
11. Bozzetti F, Mariani L (2009) Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. JPEN J Parenter Enteral Nutr 33(4):361-367.
12. Giacosa A, Frascio F, Sukkar SG et al (1997) Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italian di Nutrizione Parenterale ed Enterale 15:20-23.
13. Feliu J, González Barón M, Berrocal A et al (1992) Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. Am J Clin Oncol 15:436-440.
14. Fietkau R, Riepl M, Kettner H et al (1997) Supportive use of megestrol acetate in patients with head and neck cancer during radio (chemo)therapy. Eur J Cancer 33:75-79.
15. Bruera E, Neumann CM, Pituskin E, Calder K, Ball G, Hanson J (1999) Thalidomide in patients with cachexia due to terminal cancer: preliminary report. Ann Oncol 10(7):857-859.
16. Rowland KM Jr, Loprinzi CL, Shaw EG et al (1996) Randomized double blind placebo controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. J Clin Oncol 14:135-141.
17. Loprinzi CL, Bernath AM, Schaid DJ et al (1994) Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology 51(Suppl 1):2-7.
18. Dewys WD, Begg C, Lavin PT et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69:491-497.
19. Glare P, Sinclair C, Downing M, Stone P, Maltoni M, Vigano A (2008) Predicting survival in patients with advanced disease. Eur J Cancer 44(8):1146-1156.
20. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V et al (2008) Cachexia: a new definition. Clin Nutr 27(6):793-799.
21. Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J, Leslie WT (2000) Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 9(10):1137-1146.
22. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6-9.
23. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 3 85(5):365-376.